[Brain death, physiopathology, optimal care and hormonal therapy for cardiac donation]

Hugo Zetina-Tun1, Carlos Lezama-Urtecho, Rafael Urías-Báez

  • 1Departamento de Cirugía Cardiotorácica y Soporte Cardiopulmonar de la UMAE, Hospital General Dr. Gaudencio González Garza, Centro Médico Nacional La Raza, IMSS D.F. México, México.

Cirugia Y Cirujanos
|January 23, 2013
PubMed

Insights

Hormonal rescue therapy, using triiodothyronine, vasopressin, and methylprednisolone, improves donor heart function in brain-dead individuals. This enhances organ availability and post-transplant survival rates.

Area of Science:

  • Cardiology
  • Endocrinology
  • Transplantation Medicine

Context:

  • Terminal heart failure necessitates heart transplantation as a standard therapy.
  • Donor graft performance significantly impacts post-transplantation survival.
  • Brain death triggers detrimental physiological changes, including adrenergic storm and hormonal depletion.

Purpose:

  • To evaluate the efficacy of hormonal rescue therapy in improving donor organ quality and quantity.
  • To mitigate the negative effects of brain death on donor hearts.
  • To enhance the performance and survival rates of transplanted organs.

Summary:

  • Hormonal therapy, involving triiodothyronine, vasopressin, and methylprednisolone, has been used since 2002 to improve donor heart performance in brain-dead individuals.
  • This therapeutic approach aims to increase the number and quality of harvested organs, leading to better post-transplant outcomes.
  • Studies indicate successful outcomes, including improved organ performance, increased one-year survival, and reduced mortality.

Impact:

  • Hormonal rescue therapy enhances the availability and performance of donor organs for transplantation.
  • It has led to increased harvesting of solid organs like hearts, lungs, and kidneys.
  • Improved one-year post-transplantation survival and reduced mortality rates have been observed.

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...